Literature DB >> 28834048

Medication contaminants as a potential cause of anaphylaxis to vincristine.

David A Hill1,2, Allison Barz Leahy3, Joseph Sciasci4, Sean P O'Neill5, Anne Reilly3, Naomi Balamuth3, Steven H Seeholzer6, Jonathan M Spergel1,2, Terri F Brown-Whitehorn1.   

Abstract

Vincristine (VCR) is a vinca alkaloid and common chemotherapeutic that is used to treat multiple pediatric and adult malignancies. Despite its common use, cases of anaphylaxis to VCR are rare and typically isolated to a single individual. We report a series of eight patients with adverse reactions to VCR over the course of 11 months at a single institution, four of which progressed to anaphylaxis and one of which resulted in cardiac arrest. Mass spectrometry analysis of medication lots was performed to test for possible contaminant(s). Our findings highlight the risk of anaphylaxis during therapy with VCR.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  allergy; anaphylaxis; contaminant; mass spectrometry; vincristine

Mesh:

Substances:

Year:  2017        PMID: 28834048      PMCID: PMC5978699          DOI: 10.1002/pbc.26761

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

Review 1.  NMR spectroscopy in pharmacy.

Authors:  U Holzgrabe; B W Diehl; I Wawer
Journal:  J Pharm Biomed Anal       Date:  1998-08       Impact factor: 3.935

Review 2.  Anaphylaxis to drugs.

Authors:  Merin Kuruvilla; David A Khan
Journal:  Immunol Allergy Clin North Am       Date:  2015-03-03       Impact factor: 3.479

3.  The discovery of the vinca alkaloids--chemotherapeutic agents against cancer.

Authors:  R L Noble
Journal:  Biochem Cell Biol       Date:  1990-12       Impact factor: 3.626

Review 4.  Current position of high-resolution MS for drug quantification in clinical & forensic toxicology.

Authors:  Markus R Meyer; Andreas G Helfer; Hans H Maurer
Journal:  Bioanalysis       Date:  2014-08       Impact factor: 2.681

5.  NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.

Authors:  Viktor Háda; Zsófia Dubrovay; Agnes Lakó-Futó; János Galambos; Zoltán Gulyás; Antal Aranyi; Csaba Szántay
Journal:  J Pharm Biomed Anal       Date:  2012-10-22       Impact factor: 3.935

6.  Fatal anaphylaxis following intravenous vincristine.

Authors:  B Bhardwaj; S K Kalra; G Gupta
Journal:  Indian Pediatr       Date:  1986-11       Impact factor: 1.411

Review 7.  Acute basophilic leukemia in a child. Anaphylactoid reaction and coagulopathy secondary to vincristine-mediated degranulation.

Authors:  J C Bernini; C F Timmons; E S Sandler
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

8.  Stereocontrolled total synthesis of (+)-vincristine.

Authors:  Takeshi Kuboyama; Satoshi Yokoshima; Hidetoshi Tokuyama; Tohru Fukuyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-12       Impact factor: 11.205

9.  NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities - part I.

Authors:  Zsófia Dubrovay; Viktor Háda; Zoltán Béni; Csaba Szántay
Journal:  J Pharm Biomed Anal       Date:  2012-08-28       Impact factor: 3.935

10.  Contaminated heparin associated with adverse clinical events and activation of the contact system.

Authors:  Takashi Kei Kishimoto; Karthik Viswanathan; Tanmoy Ganguly; Subbiah Elankumaran; Sean Smith; Kevin Pelzer; Jonathan C Lansing; Nammalwar Sriranganathan; Ganlin Zhao; Zoya Galcheva-Gargova; Ali Al-Hakim; Gregory Scott Bailey; Blair Fraser; Sucharita Roy; Thomas Rogers-Cotrone; Lucinda Buhse; Mark Whary; James Fox; Moheb Nasr; Gerald J Dal Pan; Zachary Shriver; Robert S Langer; Ganesh Venkataraman; K Frank Austen; Janet Woodcock; Ram Sasisekharan
Journal:  N Engl J Med       Date:  2008-04-23       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.